{"DataElement":{"publicId":"2186021","version":"1","preferredName":"Cancer Treatment Concurrent Administered Ind-2","preferredDefinition":"the yes/no indicator whether concurrent cancer therapy was administered.","longName":"CATX_CONC_ADM_IND2","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2738396","version":"1","preferredName":"Cancer Treatment Concurrent Administered","preferredDefinition":"information related to the concurrent administration of an intervention for management of a malignant neoplasm.","longName":"CATX_CONCUR_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2738394","version":"1","preferredName":"Cancer_Treatment","preferredDefinition":"Any intervention for management of a malignant neoplasm.","longName":"C16212","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cancer Therapeutic Procedure","conceptCode":"C16212","definition":"Any intervention for management of a malignant neoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49BD3CC9-CFE5-0DB9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-03-31","modifiedBy":"ONEDATA","dateModified":"2008-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207816","version":"1","preferredName":"Concurrent Administered","preferredDefinition":"Occurring or operating at the same time.:Given.","longName":"C25456:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Concurrent","conceptCode":"C25456","definition":"Occurring or operating at the same time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-315F-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49BD3CC9-CFF2-0DB9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811871","version":"1","longName":"Colorectal","context":"CTEP"}]},{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"},{"publicId":"3303197","version":"1","longName":"Phase 1/Pilot Consortium","context":"COG"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4171062","version":"1","longName":"RTOG-1005","context":"NRG"},{"publicId":"4104941","version":"1","longName":"GOG-0281","context":"NRG"},{"publicId":"10000705","version":"1","longName":"GOG-0281","context":"NRG"},{"publicId":"10000163","version":"1","longName":"GOG-0267","context":"NRG"},{"publicId":"10000162","version":"1","longName":"GOG-0267","context":"NRG"},{"publicId":"4104918","version":"1","longName":"GOG-0267","context":"NRG"},{"publicId":"4104892","version":"1","longName":"GOG-0229O","context":"NRG"}]}],"AlternateNames":[{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"CATX_CONC_ADM_IND2","type":"USED_BY","context":"CTEP"},{"name":"CATX_CONC_ADM_IND2","type":"USED_BY","context":"COG"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"CATX_CONC_ADM_IND2","type":"USED_BY","context":"NRG"},{"name":"CANC_TX_CONC_ADMIN_IND","type":"COG GDE Short Name","context":"COG"},{"name":"ABTC","type":"USED_BY","context":"ABTC"},{"name":"CCR","type":"USED_BY","context":"CCR"},{"name":"IE_IEORRES_CROS_CONCURTX","type":"OID, CCTG","context":"CCTG"},{"name":"IE_IEORRES_INVEST","type":"OID, CCTG","context":"CCTG"}],"ReferenceDocuments":[{"name":"Concurrent use of other anti-","type":"Preferred Question Text","description":"Concurrent use of other anti-cancer therapy including chemotherapy agents, target agents, or biological agents","url":null,"context":"CTEP"},{"name":"CRF Text 3","type":"Alternate Question Text","description":"Is there a plan to administer concurrent chemotherapy for the current breast cancer","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Is the patient receiving current cancer therapy, e.g., chemotherapy, non-cytotoxic regimens, hormone therapy, or radiation therapy?","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Is there a plan for concurrent chemotherapy for the current breast cancer","url":null,"context":"CTEP"},{"name":"CRF Text5","type":"Alternate Question Text","description":"Is patient currently receiving any other anticancer or experimental drug therapy","url":null,"context":"CTEP"},{"name":"CRF Text6","type":"Alternate Question Text","description":"Not receiving any current anti-cancer therapy","url":null,"context":"CTEP"},{"name":"COG_CRF_TEXT_1","type":"Alternate Question Text","description":"Did the patient receive any anti-cancer therapy during the indicated period","url":null,"context":"CTEP"},{"name":"CRF Text8","type":"Alternate Question Text","description":"Is the patient receiving any other anti-cancer or investigational agents?","url":null,"context":"CTEP"},{"name":"CRf Text7","type":"Alternate Question Text","description":"Will the patient have other anti-cancer therapy while on study treatment?","url":null,"context":"CTEP"},{"name":"CRF Text9","type":"Alternate Question Text","description":"Will patient be receiving concurrent treatment with other investigational or anti-neoplastic agents?","url":null,"context":"CTEP"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Is patient currently receiving any other anticancer agents?","url":null,"context":"COG"},{"name":"CRF Text 10","type":"Alternate Question Text","description":"Access to other investigational agents","url":null,"context":"CTEP"},{"name":"COG_CRF_TEXT_2","type":"Alternate Question Text","description":"Is patient currently receiving any other anticancer or investigational drug therapy","url":null,"context":"COG"},{"name":"NRG_CRF text","type":"Alternate Question Text","description":"Will the patient have any additional planned concomitant, non-protocol directed anti-cancer therapy?","url":null,"context":"NRG"},{"name":"NRG_CRF Text 2","type":"Alternate Question Text","description":"Is there a plan to administer first-line standard systemic therapy for metastatic breast cancer?","url":null,"context":"NRG"},{"name":"NRG_CRF Text 3","type":"Alternate Question Text","description":"Is the patient currently receiving any anti-cancer therapy including chemotherapy, radiation therapy, biologic therapy, immunotherapy, hormonal therapy or investigational therapy?","url":null,"context":"NRG"},{"name":"CRF Text11","type":"Alternate Question Text","description":"Planned concomitant use of Optune device","url":null,"context":"Alliance"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Is patient currently receiving active anti-neuroblastoma cytotoxic chemotherapy?","url":null,"context":"COG"},{"name":"CRF Text 4","type":"Alternate Question Text","description":"Did the patient have systemic anticancer therapy within 3 weeks prior to study entry","url":null,"context":"CTEP"},{"name":"ABTC-1602 Question","type":"Alternate Question Text","description":"Is the patient planning to use Novo-TT (Optune)?","url":null,"context":"ABTC"},{"name":"COG CRF Text 4","type":"Alternate Question Text","description":"Is patient currently receiving other anticancer agents?","url":null,"context":"COG"},{"name":"COG CRF Text 10","type":"Alternate Question Text","description":"Is the patient currently receiving other anti-cancer agents?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Has the patient participated in a study of an investigational agent and received cancer-directed study therapy within 4 weeks prior to registration?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_1","type":"Alternate Question Text","description":"Has the patient participated in a study of an investigational agent and received cancer-directed study therapy within 4 weeks prior to Step 1 registration?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_2","type":"Alternate Question Text","description":"Is the patient receiving any other investigational agent?","url":null,"context":"NRG"},{"name":"COG CRF Text 5","type":"Alternate Question Text","description":"Did the patient receive concurrent anticancer therapy, including chemotherapy, immunotherapy, or biologic therapy during this reporting period?","url":null,"context":"COG"},{"name":"COG CRF Text 01","type":"Alternate Question Text","description":"Is patient currently receiving any other anticancer or experimental drug therapy?","url":null,"context":"COG"},{"name":"COG CRF Text 6","type":"Alternate Question Text","description":"Is the patient currently receiving other anti-cancer agents, except hydroxyurea?","url":null,"context":"COG"},{"name":"CRF TEXT12","type":"Alternate Question Text","description":"If Randomized to Arm 1, does the patient intend to use NovoTTF (Optune)?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_3","type":"Alternate Question Text","description":"Is the patient currently participating and receiving cancer-directed study therapy, or have they participated in a study of an investigational agent and received cancer-directed study therapy within 4 weeks prior to enrollment?","url":null,"context":"NRG"},{"name":"Concurrent chemotherapy","type":"Alternate Question Text","description":"Concurrent chemotherapy","url":null,"context":"CCR"},{"name":"COG CRF Text 11","type":"Alternate Question Text","description":"Is patient receiving other ongoing anticancer therapy?","url":null,"context":"COG"},{"name":"CRF Text13","type":"Alternate Question Text","description":"Does the patient have a planned initiation of definitive (potentially curative) concurrent chemo-radiation?","url":null,"context":"Alliance"},{"name":"NRG_eCRF_Text_4","type":"Alternate Question Text","description":"Is the patient currently receiving any other investigational agents or has the patient received an investigational agent within 4 weeks of registration?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_5","type":"Alternate Question Text","description":"Is the patient currently receiving any other investigational agents or has the patient received an investigational agent within 4 weeks of study registration?","url":null,"context":"NRG"},{"name":"COG CRF Text 12","type":"Alternate Question Text","description":"Was anti-cancer therapy given for relapse?","url":null,"context":"COG"},{"name":"COG CRF Text 13","type":"Alternate Question Text","description":"Was anti-cancer therapy given for relapse prevention?","url":null,"context":"COG"},{"name":"COG CRF Text 7","type":"Alternate Question Text","description":"Was the anti-cancer therapy given to treat detectable disease that did not meet the definition of relapse?","url":null,"context":"COG"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Is the patient receiving concurrent anticancer therapy?","url":null,"context":"NRG"},{"name":"CCTG_01","type":"Alternate Question Text","description":"No plans to administer additional (non-protocol) systemic anti-cancer therapy beyond those permitted by protocol.","url":null,"context":"CCTG"},{"name":"CCTG_02","type":"Alternate Question Text","description":"Treatment with other investigational drugs or anti-cancer therapy within 28 days prior to enrollment.","url":null,"context":"CCTG"},{"name":"COG CRF Text 14","type":"Alternate Question Text","description":"Was anti-cancer therapy given for relapse prevention (no detectable disease)?","url":null,"context":"COG"}],"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"DFE97FAD-EF3A-722B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-23","modifiedBy":"GDEEN","dateModified":"2023-10-19","changeDescription":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"9/27/23 Added AQT and alt OID, CCTG for ticket number CADSR0002884 cjl. 3/7/23 added 1 alt OID and 1 AQT for CCTG ticket request CADSR0002117 cjl.","unresolvedIssues":null,"deletedIndicator":"No"}}